P-87 Real-world data of nivolumab in advanced hepatocellular carcinoma: A multi-centric and retrospective study

Sardinha, M.; Simão, Diana; Reis, Ana Filipa; Spencer, Ana Sofia; Parmanande, Anuraj; Saraiva, Renato Ângelo; Calinas, Filipe; Filipe, F.; Winckler, P.; Luz, Ricardo da; Martins, Mário Rino; Gramaça, João; Ramos, Maria da Conceição Pereira; Cadavez, E.; Moura, Miguel Carneiro de; Gil, Leire; Presa, José; Carrola, Paulo; Pinho, Inês; Carvalho, Sónia

doi:10.1016/j.annonc.2021.05.142

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, efficacy was approximately half of that observed in Checkmate 040. Results from this study are in agreement with latest evidence indicating that the survival of patients with aHCC treated with nivolumab is correlated to the Child-Pugh liver function score at baseline[ 95 ], as reported in aforementioned studies as well[ 92 - 94 ]. Equally, the finding that unselected Child-Pugh B and above patients exhibit an unsatisfactory response to and survival with nivolumab has been echoed in another retrospective study of 203 HCC patients; (ORR 3% vs 16% in Child–Pugh class B/A, P = 0.01; mOS 11.3 vs 42.9 wk in Child–Pugh class B/A, adjusted HR, 2.10, P < 0.001)[ 96 ].…”

Section: Real-world Data For Immunotherapy In Hccsupporting

confidence: 92%

Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances

Rallis¹,

Makrakis²,

Ziogas³

et al. 2022

WJCO

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality worldwide. HCC is an inflammation-associated immunogenic cancer that frequently arises in chronically inflamed livers. Advanced HCC is managed with systemic therapies; the tyrosine kinase inhibitor (TKI) sorafenib has been used in 1 st -line setting since 2007. Immunotherapies have emerged as promising treatments across solid tumors including HCC for which immune checkpoint inhibitors (ICIs) are licensed in 1 st - and 2 nd -line treatment setting. The treatment field of advanced HCC is continuously evolving. Several clinical trials are investigating novel ICI candidates as well as new ICI regimens in combination with other therapeutic modalities including systemic agents, such as other ICIs, TKIs, and anti-angiogenics. Novel immunotherapies including adoptive cell transfer, vaccine-based approaches, and virotherapy are also being brought to the fore. Yet, despite advances, several challenges persist. Lack of real-world data on the use of immunotherapy for advanced HCC in patients outside of clinical trials constitutes a main limitation hindering the breadth of application and generalizability of data to this larger and more diverse patient cohort. Consequently, issues encountered in real-world practice include patient ineligibly for immunotherapy because of contraindications, comorbidities, or poor performance status; lack of response, efficacy, and safety data; and cost-effectiveness. Further real-world data from high-quality large prospective cohort studies of immunotherapy in patients with advanced HCC is mandated to aid evidence-based clinical decision-making. This review provides a critical and comprehensive overview of clinical trials and real-world data of immunotherapy for HCC, with a focus on ICIs, as well as novel immunotherapy strategies underway.

show abstract

Section: Real-world Data For Immunotherapy In Hccsupporting

confidence: 92%

Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances

Rallis¹,

Makrakis²,

Ziogas³

et al. 2022

WJCO

View full text Add to dashboard Cite

show abstract

“…The most common 2L treatments following sorafenib were nivolumab (37.5%), regorafenib (23.6%), and capecitabine (6.9%); other real-world studies have demonstrated the effectiveness of these therapies when used as 2L treatments following sorafenib. In another real-world study, survival of 23 patients with advanced HCC who received nivolumab after 1L sorafenib treatment was shown to relate with CP score at the start of treatment; CP Class A at initiation of nivolumab was associated with superior OS (p = 0.014) [ 33 ]. Experience of treatment sequencing from sorafenib to regorafenib in the real-world setting has also been reported with an increase in OS and tolerable safety profile, similar to that observed in clinical trials [ 34–36 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcomes By Child-Pugh Class in Patients With Advanced Hepatocellular Carcinoma in a Community Oncology Setting

et al. 2023

View full text Add to dashboard Cite

Aim: Many pivotal trials in advanced hepatocellular carcinoma (HCC) require participants to have Child-Pugh A disease. However, many patients in real-world practice are Child-Pugh B or C. This study examined treatment patterns and clinical outcomes in patients with advanced HCC treated with first-line systemic therapy. Materials & methods: In this retrospective study, patients with HCC treated with first-line systemic therapy (2010–2017) were identified from US Oncology Network records. Outcomes included overall survival and progression-free survival, by Child-Pugh Class and prior liver-directed therapy. Results: Of 352 patients, 78.7% were Child-Pugh A or B, 96.6% received first-line sorafenib, and 33.8% received first-line-prior liver-directed therapy. Survival outcomes were similar for Child-Pugh A or B, and longer after first-line prior liver-directed therapy. Conclusion: First-line systemic therapy is beneficial in patients with Child-Pugh A or B, and after first-line prior liver-directed therapy. These findings may help position systemic therapy in the community setting.

show abstract

“…Another major challenge in immunotherapy for HCC is the lack of markers to predict the effect of treatment. The latest report in the ESMO 2021 Annual Meeting shows that the survival of patients with advanced HCC treated with nivolumab was related to the Child-Pugh (C-P) liver function score at baseline (136). However, other methods of immunotherapy are mostly still in the early clinical stage, and there are no good indicators for predicting the therapeutic effect.…”

Section: Challenges and Opportunitiesmentioning

confidence: 99%

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Liu

Liang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional therapeutic options that will help only a limited percentage of HCC patients. Cancer immunotherapy has achieved dramatic advances in recent years and provides new opportunities to treat HCC. However, HCC has various etiologies and can evade the immune system through multiple mechanisms. With the rapid development of genetic engineering and synthetic biology, a variety of novel immunotherapies have been employed to treat advanced HCC, including immune checkpoint inhibitors, adoptive cell therapy, engineered cytokines, and therapeutic cancer vaccines. In this review, we summarize the current landscape and research progress of different immunotherapy strategies in the treatment of HCC. The challenges and opportunities of this research field are also discussed.

show abstract

P-87 Real-world data of nivolumab in advanced hepatocellular carcinoma: A multi-centric and retrospective study

Cited by 4 publications

References 0 publications

Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances

Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances

Clinical Outcomes By Child-Pugh Class in Patients With Advanced Hepatocellular Carcinoma in a Community Oncology Setting

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Contact Info

Product

Resources

About